Yartey Samuel Nee-Amugie, Kungu Frederick, Asantewaa Anastasia Akosua, Donkor Eric S
Department of Medical Microbiology, University of Ghana Medical School, Korle Bu, P. O. Box KB 4236, Accra, Ghana.
Sci Rep. 2025 Aug 13;15(1):29625. doi: 10.1038/s41598-025-10695-7.
Extended-spectrum beta-lactamase (ESBL)-producing bacteria are associated with life-threatening infections with limited treatment options worldwide. In this review, we assess the circulating ESBL-producing bacterial clones from human, animal, and environmental sources in West Africa, through a One Health approach. A systematic search in PubMed, Scopus, and Web of Science identified 485 records, with 38 studies analysed. Data were organized thematically and pooled prevalence estimates calculated through a random-effects meta-analysis. Results showed a 16.8% (95% CI [12.1; 22.1]) prevalence of ESBL-producing bacteria, with Escherichia coli (64%) being the most frequently detected species. Humans were the most affected (20.4%), followed by animals (12.8%) and the environment (9.3%). Among the 153 identified bacterial clones, ST10, ST410, ST58, ST155, ST4684, ST2178, and ST37, found majorly in E. coli, occurred across multiple sources, suggesting cross-sectoral transmission. The blaCTX-M gene, prevalent with several fluoroquinolone and aminoglycoside resistance genes, was often on conjugative IncF plasmids (50.0%), suggesting high horizontal transmission potential. The emerging ESBL gene, GES (1.2%) was also detected in Pseudomonas aeruginosa. The findings reinforce the need for robust antimicrobial resistance monitoring and intervention strategies in West Africa. A regional One Health-based approach is necessary to curtail the spread of resistant bacterial clones and safeguard the efficacy of available treatment options.
产超广谱β-内酰胺酶(ESBL)细菌与全球范围内危及生命的感染相关,且治疗选择有限。在本综述中,我们通过“同一健康”方法评估了西非人类、动物和环境来源中产ESBL细菌克隆的传播情况。在PubMed、Scopus和Web of Science中进行系统检索,共识别出485条记录,并对38项研究进行了分析。数据按主题进行整理,并通过随机效应荟萃分析计算合并患病率估计值。结果显示,产ESBL细菌的患病率为16.8%(95%置信区间[12.1;22.1]),其中大肠埃希菌(64%)是最常检测到的菌种。人类受影响最大(20.4%),其次是动物(12.8%)和环境(9.3%)。在153个已识别的细菌克隆中,主要存在于大肠埃希菌中的ST10、ST410、ST58、ST155、ST4684、ST2178和ST37,在多个来源中均有出现,表明存在跨部门传播。blaCTX-M基因与几种氟喹诺酮和氨基糖苷类耐药基因共同流行,通常存在于接合性IncF质粒上(50.0%),表明其水平传播潜力较高。新兴的ESBL基因GES(1.2%)也在铜绿假单胞菌中被检测到。这些发现强化了在西非进行强有力的抗菌药物耐药性监测和干预策略的必要性。基于“同一健康”的区域方法对于遏制耐药细菌克隆的传播和保障现有治疗选择的疗效至关重要。